A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

NCT04047290 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms Malignant

Interventions

DRUG: AK112

Sponsor

Akesobio Australia Pty Ltd